Advertisement
Platinum Priority – Brief Correspondence Editorial by James Porter, Scott Eggener, Erik Castle and Phillip Pierorazio on pp. 610–611 of this issue| Volume 76, ISSUE 5, P607-609, November 01, 2019

Adverse Surgical Outcomes Associated with Robotic Retroperitoneal Lymph Node Dissection Among Patients with Testicular Cancer

      Abstract

      Surgery for metastatic testicular disease has been an essential factor in the long-term cure rates for men with testicular germ cell tumors. Robotic approaches to retroperitoneal lymph node dissection (R-RPLND) have been proposed as an alternative to open surgery with few if any adverse events reported. We report the clinical course for five recent patients referred to our center for recurrences after R-RPLND, focusing on recurrence patterns, treatment burden, and treatment-related morbidity and mortality. The median time to recurrence after R-RPLND was 259 d. The recurrence patterns after R-RPLND were aberrant from our past experience in managing recurrences after open RPLND. One man experienced an in-field recurrence located in close proximitry to an undivided lumbar vessel. Four patients had out-of-field recurrence in abnormal locations: pericolic space invading the sigmoid colon, peritoneal carcinomatosis with a perinephric mass, large-volume liver lesions with suprahilar disease extending into the retrocrural space, and lymph nodes in the celiac axis. The treatment burden was high: the five men were subjected to 12 different chemotherapy regimens and three underwent additional surgeries. Three patients developed significant cisplatin-induced toxicity. One patient died due to progression of testicular cancer after failing all chemotherapy and surgical options.

      Patient summary

      We report our initial experience in managing patients with testicular cancer referred to our institution after robotic retroperitoneal lymph node dissection (RPLND). We found that the recurrences were highly variable and in unusual locations and were associated with a high treatment burden. We conclude that further investigation into the safety and long-term oncologic efficacy of robotic RPLND is necessary before widespread implementation.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to European Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pearce S.M.
        • Golan S.
        • Gorin M.A.
        • et al.
        Safety and early oncologic effectiveness of primary robotic retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer.
        Eur Urol. 2017; 71: 476-482https://doi.org/10.1016/j.eururo.2016.05.017
        • Ramirez P.T.
        • Frumovitz M.
        • Pareja R.
        • et al.
        Minimally invasive versus abdominal radical hysterectomy for cervical cancer.
        N Engl J Med. 2018; 379: 1895-1904https://doi.org/10.1056/NEJMoa1806395
        • Melamed A.
        • Margul D.J.
        • Chen L.
        • et al.
        Survival after minimally invasive radical hysterectomy for early-stage cervical cancer.
        N Engl J Med. 2018; 379: 1905-1914https://doi.org/10.1056/NEJMoa1804923
        • Albany C.
        • Adra N.
        • Snavely A.C.
        • et al.
        Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ cell tumors.
        Ann Oncol. 2018; 29: 341-346https://doi.org/10.1093/annonc/mdx731
        • Pedrosa J.A.
        • Masterson T.A.
        • Rice K.R.
        • Bihrle R.
        • Beck S.D.W.
        • Foster R.S.
        Reoperative retroperitoneal lymph node dissection for metastatic germ cell tumors: analysis of local recurrence and predictors of survival.
        J Urol. 2014; 191: 1777-1782https://doi.org/10.1016/j.juro.2014.01.010